scholarly journals Association Between Interleukin-6 and Head and Neck Squamous Cell Carcinoma: A Systematic Review

2021 ◽  
Vol 14 (1) ◽  
pp. 50-60
Author(s):  
Uzdan Uz ◽  
Görkem Eskiizmir

Interleukin-6 (IL-6) is a proinflammatory cytokine which plays an important role in several regulatory mechanisms of cancer. Moreover, experimental and clinical studies have reported that IL-6 targeted therapies might provide significant benefits for cancer treatment. The purpose of this systematic review is to evaluate IL-6 activity in patients with head and neck squamous cell carcinoma (HNSCC). A systematic review of the association between serum, saliva and tumor IL-6 and HNSCC was developed on PubMed/Medline in the publication range from January 1995 to January 2019. Our literature analysis demonstrated that overexpression and elevated serum and/or saliva IL-6 concentrations in patients with HNSCC are related to poor survival and oncological outcomes. Although there is a correlation between IL-6 concentrations and tumorigenicity, it is noteworthy that IL-6 targeted therapies are generally performed in vitro and in experimental studies. Therefore, prospective, randomized clinical trials are required that focus on IL-6 targeted therapies for the treatment of HNSCC.

2015 ◽  
Vol 4 (7) ◽  
pp. 1101-1116 ◽  
Author(s):  
Justin E. Swartz ◽  
Ajit J. Pothen ◽  
Inge Stegeman ◽  
Stefan M. Willems ◽  
Wilko Grolman

2020 ◽  
Vol 21 (19) ◽  
pp. 7255
Author(s):  
Shrabon Hasnat ◽  
Roosa Hujanen ◽  
Bright I. Nwaru ◽  
Tuula Salo ◽  
Abdelhakim Salem

Head and neck squamous cell carcinoma (HNSCC) is a group of tumours which exhibit low 5 year survival rates. Thus, there is an urgent need to identify biomarkers that may improve the clinical utility of patients with HNSCC. Emerging studies support a role of toll-like receptors (TLRs) in carcinogenesis. Therefore, this systematic review and meta-analysis was performed to assess the prognostic value of TLR immunoexpression in HNSCC patients. We compiled the results of thirteen studies comprising 1825 patients, of which six studies were deemed qualified for quantitative synthesis. The higher immunoexpression of TLR-1 to 5 and 9 was associated with a worsening of the clinical parameters of patients with HNSCC. Furthermore, induced levels of TLR-3, 4, 5, 7 and 9 were found to predict the patients’ survival time. The meta-analysis revealed that TLR-7 overexpression is associated with a decreased mortality risk in HNSCC patients (HR 0.51; 95%CI 0.13–0.89; I2 34.6%), while a higher expression of TLR-5 predicted shorter, but non-significant, survival outcome. In conclusion, this review suggests that TLRs may represent some prognostic value for patients with HNSCC. However, due to small sample sizes and other inherent methodological limitations, more well designed studies across different populations are still needed before TLRs can be recommended as a reliable clinical risk-stratification tool.


Oral Oncology ◽  
2019 ◽  
Vol 90 ◽  
pp. 67-73 ◽  
Author(s):  
Mustafa Ghanizada ◽  
Kathrine Kronberg Jakobsen ◽  
Christian Grønhøj ◽  
Christian von Buchwald

Sign in / Sign up

Export Citation Format

Share Document